Target Market Fit Biotech startup focusing on IBS digestive health and enzyme-based food solutions presents a clear B2B and B2C sales path with potential partnerships in nutraceuticals, food processing, and dietary supplement distribution to reach the 40M Americans affected by IBS.

Strategic Partnerships Leverage connections with food manufacturers, grocers, and healthcare providers to co-brand or license FODZYME technology, expanding reach into product lines for garlic, onion, wheat, and banana triggers, and exploring private-label opportunities.

Funding & Validation Recognized as a finalist in innovation programs and securing early-stage funding signals credibility; use these milestones in outreach to financial partners, strategic investors, and potential customers seeking proven innovation with regulatory and clinical validation potential.

Digital Channels Active web presence and e-commerce infrastructure (Shopify, Webflow) combined with AWS and Google Workspace support enable targeted digital marketing, content collaborations, and direct-to-consumer sales experiments to test demand and drive lead generation.

Growth Signals Revenue in the low multi-million range with modest funding suggests nimble operations and scalability potential; position to scale through channel expansion, contract manufacturing, and broader enzyme applications for digestive health products.